Detalles de la búsqueda
1.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068901
2.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
3.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36495879
4.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 205(3): 589-598, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38456970
5.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
6.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239405
7.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
8.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
9.
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Breast Cancer Res Treat
; 187(2): 467-476, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33748921
10.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 22(1): 9, 2020 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31969184
11.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 21(1): 133, 2019 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31796073
12.
[THE FRENCH ANATOMICAL XAVIER BICHAT (1771 - 1802). FUNDATOR OF DOCTRINE OF TISSUES. BIOGRAPHICAL MEMORY BEFORE HIS GRAVE]. / EL ANATOMICO FRANCES XAVIER BICHAT (1771 - 1802). FUNDADOR DE LA DOCTRINA TISULAR. RECUERDO BIOGRAFICO ANTE SU TUMBA.
An R Acad Nac Med (Madr)
; 131(1): 257-71; discussion 272, 2014.
Artículo
en Español
| MEDLINE | ID: mdl-27386683
13.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
J Nucl Med
; 65(5): 708-713, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575192
14.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.
EClinicalMedicine
; 71: 102520, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38638399
15.
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer.
Front Oncol
; 13: 1048242, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37496662
16.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Neuro Oncol
; 25(1): 157-166, 2023 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35639825
17.
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
Clin Cancer Res
; 29(1): 67-80, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36165912
18.
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Cancer Res Commun
; 3(9): 1853-1861, 2023 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37712875
19.
Effects of binge drinking during adolescence and emerging adulthood on the brain: A systematic review of neuroimaging studies.
Neurosci Biobehav Rev
; 137: 104637, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35339481
20.
Effects of Persistent Binge Drinking on Brain Structure in Emerging Adults: A Longitudinal Study.
Front Psychiatry
; 13: 935043, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35815019